FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386880487> ?p ?o ?g. }

• W4386880487 abstract "Abstract Fezolinetant has emerged as a potential treatment by targeting neurokinin B (NKB) signalling disruption and Kisspeptin/neurokinin B/dynorphin (KNDy) neuron activation in the hypothalamus. We aim to evaluate Fezolinetant's efficacy and safety in treating menopause-related VMS. We searched on PubMed, Web of Science (WOS), Scopus, and Cochrane till June 19th, 2023. All relevant randomized clinical trials (RCTs) were included. Our review included all studies that evaluate the efficacy and safety of Fezolinetant. Data were extracted and pooled using Review Manager Software (RevMan version 5.3). The meta-analysis of six studies showed Fezolinetant's significant improvement in vasomotor symptoms (VMSs) compared to placebo in most of the outcomes. Fezolinetant reduces VMS frequency, with mean differences (MDs) of -2.66 (4 weeks) and − 2.46 (12 weeks). VMS severity becomes better, particularly with Fezolinetant 30 mg (MD -0.16, -0.20) and Fezolinetant 45 mg (MD -0.23, -0.29). Additionally, Fezolinetant enhances outcomes in GCS vasomotor symptoms score (MD -2.53, -3.65) and HFRDIS score (MD -1.85, -1.71). PROMIS SD SF 8b reveals favorable results with Fezolinetant 30 mg (MD -1.15, -0.61) and Fezolinetant 45 mg (MD -2.25, -1.55). Regarding the MENQoL total score, Fezolinetant 30 mg (MD -0.45, -0.33) and Fezolinetant 45 mg (MD -0.57, -0.48) show improvement. The favorable tolerability and safety of Fezolinetant make it a promising therapy option for post-menopausal women with VMSs." @default.
• W4386880487 created "2023-09-21" @default.
• W4386880487 creator A5005801635 @default.
• W4386880487 creator A5006559090 @default.
• W4386880487 creator A5013117011 @default.
• W4386880487 creator A5032648464 @default.
• W4386880487 creator A5051408336 @default.
• W4386880487 creator A5053353374 @default.
• W4386880487 creator A5092575814 @default.
• W4386880487 creator A5092906794 @default.
• W4386880487 creator A5092906795 @default.
• W4386880487 date "2023-09-21" @default.
• W4386880487 modified "2023-09-27" @default.
• W4386880487 title "Efficacy and safety of Fezolinetant in moderate to severe vasomotor symptoms associated with menopause: A systematic review and meta-analysis" @default.
• W4386880487 cites W1556275621 @default.
• W4386880487 cites W1973157699 @default.
• W4386880487 cites W1995495198 @default.
• W4386880487 cites W2019278627 @default.
• W4386880487 cites W2046860639 @default.
• W4386880487 cites W2062438282 @default.
• W4386880487 cites W2117920697 @default.
• W4386880487 cites W2123516442 @default.
• W4386880487 cites W2149671999 @default.
• W4386880487 cites W2162957019 @default.
• W4386880487 cites W2215572913 @default.
• W4386880487 cites W2483745688 @default.
• W4386880487 cites W2567362164 @default.
• W4386880487 cites W2590754488 @default.
• W4386880487 cites W2604269555 @default.
• W4386880487 cites W2615609848 @default.
• W4386880487 cites W2969110138 @default.
• W4386880487 cites W2970702930 @default.
• W4386880487 cites W2989337457 @default.
• W4386880487 cites W2998507698 @default.
• W4386880487 cites W3007655640 @default.
• W4386880487 cites W3008125481 @default.
• W4386880487 cites W3138571013 @default.
• W4386880487 cites W3139352829 @default.
• W4386880487 cites W3158189637 @default.
• W4386880487 cites W3165078348 @default.
• W4386880487 cites W4384625903 @default.
• W4386880487 cites W4385507225 @default.
• W4386880487 doi "https://doi.org/10.21203/rs.3.rs-3324690/v1" @default.
• W4386880487 hasPublicationYear "2023" @default.
• W4386880487 type Work @default.
• W4386880487 citedByCount "0" @default.
• W4386880487 crossrefType "posted-content" @default.
• W4386880487 hasAuthorship W4386880487A5005801635 @default.
• W4386880487 hasAuthorship W4386880487A5006559090 @default.
• W4386880487 hasAuthorship W4386880487A5013117011 @default.
• W4386880487 hasAuthorship W4386880487A5032648464 @default.
• W4386880487 hasAuthorship W4386880487A5051408336 @default.
• W4386880487 hasAuthorship W4386880487A5053353374 @default.
• W4386880487 hasAuthorship W4386880487A5092575814 @default.
• W4386880487 hasAuthorship W4386880487A5092906794 @default.
• W4386880487 hasAuthorship W4386880487A5092906795 @default.
• W4386880487 hasBestOaLocation W43868804871 @default.
• W4386880487 hasConcept C118303440 @default.
• W4386880487 hasConcept C126322002 @default.
• W4386880487 hasConcept C142724271 @default.
• W4386880487 hasConcept C168563851 @default.
• W4386880487 hasConcept C170493617 @default.
• W4386880487 hasConcept C197934379 @default.
• W4386880487 hasConcept C204787440 @default.
• W4386880487 hasConcept C27081682 @default.
• W4386880487 hasConcept C2776214587 @default.
• W4386880487 hasConcept C2776478404 @default.
• W4386880487 hasConcept C2776533618 @default.
• W4386880487 hasConcept C2778375690 @default.
• W4386880487 hasConcept C2778562196 @default.
• W4386880487 hasConcept C2781359426 @default.
• W4386880487 hasConcept C71924100 @default.
• W4386880487 hasConcept C95190672 @default.
• W4386880487 hasConceptScore W4386880487C118303440 @default.
• W4386880487 hasConceptScore W4386880487C126322002 @default.
• W4386880487 hasConceptScore W4386880487C142724271 @default.
• W4386880487 hasConceptScore W4386880487C168563851 @default.
• W4386880487 hasConceptScore W4386880487C170493617 @default.
• W4386880487 hasConceptScore W4386880487C197934379 @default.
• W4386880487 hasConceptScore W4386880487C204787440 @default.
• W4386880487 hasConceptScore W4386880487C27081682 @default.
• W4386880487 hasConceptScore W4386880487C2776214587 @default.
• W4386880487 hasConceptScore W4386880487C2776478404 @default.
• W4386880487 hasConceptScore W4386880487C2776533618 @default.
• W4386880487 hasConceptScore W4386880487C2778375690 @default.
• W4386880487 hasConceptScore W4386880487C2778562196 @default.
• W4386880487 hasConceptScore W4386880487C2781359426 @default.
• W4386880487 hasConceptScore W4386880487C71924100 @default.
• W4386880487 hasConceptScore W4386880487C95190672 @default.
• W4386880487 hasLocation W43868804871 @default.
• W4386880487 hasOpenAccess W4386880487 @default.
• W4386880487 hasPrimaryLocation W43868804871 @default.
• W4386880487 hasRelatedWork W1966047811 @default.
• W4386880487 hasRelatedWork W2003042623 @default.
• W4386880487 hasRelatedWork W202460821 @default.
• W4386880487 hasRelatedWork W2032187519 @default.
• W4386880487 hasRelatedWork W2068849886 @default.
• W4386880487 hasRelatedWork W2109235243 @default.
• W4386880487 hasRelatedWork W2147606462 @default.
• W4386880487 hasRelatedWork W2412493536 @default.

• next